| Study name | Trial/author, year | Was randomization carried out appropriately? | Was the concealment of treatment allocation adequate? | Were the care providers, participants, and outcome assessors blind to treatment allocation? | Were the groups similar at the outset of the study in terms of prognostic factors, for example, severity of disease? | Were there any unexpected imbalances in drop-outs between groups? | Is there any evidence to suggest that the authors measured more outcomes than they reported? | Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were appropriate methods used to account for missing data? |
| BREVACTA | Kivitz, 2014; Olech, 2013 (abstract) | Yes | Yes | Yes | Yes | No | No | Yes | TOWARD | Genovese, 2008 | Unclear | Unclear | Yes | Yes | No | No | Yes | REALISTIC | Weinblatt, 2012 | Yes | Yes | Yes | Yes | No | No | Yes | ROSE | Yazici, 2012 | Unclear | Unclear | Yes | Yes | No | No | Yes | ACQUIRE | Genovese, 2011 | Yes | Unclear | Yes | Yes | No | No | Yes | AMPLE | Weinblatt, 2013 | Unclear | Unclear | No | Yes | No | No | Yes | AUGUST II | van Vollenhoven, 2011 | Yes | Yes | Yes | Yes | No | No | Yes | ACT–RAY | Dougados, 2013 | Yes | Yes | Yes | Yes | No | No | Yes | ADACTA | Gabay, 2013 | Yes | Yes | Yes | Yes | No | No | Yes | ABT-Kremer 1 | Kremer, 2003; Kremer, 2005 | Yes | Yes | Yes | Yes | No | No | Unclear | ABT-Kremer 2 | Kremer, 2006; Russell, 2007 | Yes | Yes | Yes | Yes | No | No | Yes | ATTEST | Schiff, 2008 | Yes | Unclear | Yes | Yes | No | No | Yes | ADA–Van de Putte 2 | Van de Putte, 2004 | Yes | Yes | Yes | Yes | No | No | Yes | ADA–Van de Putte 1 | Van de Putte, 2003 | Unclear | Unclear | Yes | Yes | No | No | Yes | ARMADA | Weinblatt, 2003 | Yes | Yes | Yes | Yes | No | No | Yes | ADA–Keystone | Keystone, 2004 | Unclear | Unclear | Yes | Yes | No | No | Yes | FAST4WARD | Fleischmann, 2009 | Yes | Yes | Yes | Yes | No | No | Yes | RAPID 1 | Keystone, 2008; Strand, 2009 | Unclear | Unclear | Yes | Yes | No | No | Yes | RAPID 2 | Smolen, 2009; Strand, 2011 | Unclear | Unclear | Yes | Yes | No | No | Yes | NCT00544154 | Choy, 2012 | Yes | Yes | Yes | Yes | No | No | Yes | ETN–Mathias/Moreland | Moreland, 1999; Mathias, 2000 | Yes | Yes | Yes | Yes | No | No | Yes | ETN–Weinblatt | Weinblatt, 1999 | Yes | Yes | Yes | Yes | No | No | Unclear | ADORE | Van Riel, 2006; van Riel, 2008 | Unclear | Unclear | No | Yes | No | No | Yes | ETN–Combe | Combe, 2006; Combe, 2009 | Unclear | Unclear | Yes | Yes | No | No | Yes | GLB–Kay | Kay, 2008 | Yes | Yes | Yes | Yes | No | No | Unclear | GO–FORWARD | Keystone, 2009; Genovese, 2012 | Yes | Yes | Yes | Yes | No | No | Unclear | ATTRACT | Lipsky, 2000; Maini, 1999 | Yes | Yes | Yes | Yes | No | No | Yes | START | Westhovens, 2006 | Unclear | Unclear | Yes | Yes | No | No | Yes | CHARISMA | Maini, 2006 | Yes | Yes | Yes | Yes | No | No | Yes | OPTION | Smolen, 2008 | Yes | Yes | Yes | Yes | No | No | Yes | LITHE | Kremer, 2011; Fleischmann, 2013 | Yes | Yes | Yes | Yes | No | No | Yes | ORAL-Solo (Pfizer A3921045) | Fleishmann, 2012 | Yes | Yes | Yes | Yes | No | No | Yes | TOFA monotherapy (Pfizer A3921035) | Fleischmann, 2012 | Unclear | Unclear | Yes | Yes | No | No | Unclear | ORAL-Standard (Pfizer A3921064) | van Vollenhoven, 2012 | Yes | Yes | Unclear | Yes | No | No | Unclear | TOFA+MTX–Kremer (Pfizer A3921025) | Kremer, 2012 | Unclear | Unclear | Yes | Yes | No | No | Unclear | ORAL-Scan (Pfizer A3921044) | Van der Heijde, 2013; van der Heijde, 2012; van der Heijde, 2011 | Yes | Yes | Yes | Yes | No | No | Unclear |
|
|